Somatostatin Receptor Assessment and the Role of Peptide Receptor Radionuclide Therapy in Progressive Small Bowel Neuroendocrine Tumor

This segment examines the central role of somatostatin receptor expression in guiding treatment decisions for progressive small bowel neuroendocrine tumor. The discussion emphasizes the importance of reassessing receptor status at the time of progression, often using functional imaging, to confirm eligibility for peptide receptor radionuclide therapy. Dr Lieu notes that receptor expression may change over time, making reassessment clinically meaningful even in patients previously known to be receptor positive.

The conversation transitions to how key clinical trial data supporting peptide receptor radionuclide therapy have influenced practice patterns in progressive small bowel neuroendocrine tumor. Improvements in progression free outcomes and objective responses have established this modality as a cornerstone option for appropriately selected patients. The speakers discuss how these data translate into routine care and influence placement of radioligand therapy within treatment sequencing.

Patient counseling is highlighted as a critical component of therapy selection. Dr Lieu describes how expected benefits, potential toxicities, and long term considerations are discussed with patients to support shared decision making. Treatment logistics, coordination across multidisciplinary teams, and monitoring strategies are also addressed.

This segment reinforces peptide receptor radionuclide therapy as a highly effective option for patients with somatostatin receptor positive progressive small bowel neuroendocrine tumor and underscores the importance of careful patient selection and communication.